Evidence map›Paper›PMID 28861666›Full record

ArticleJournal of neuro-oncology2017

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Birthe Krogh Rasmussen, Steinbjørn Hansen, René J Laursen, Michael Kosteljanetz, Henrik Schultz, Bente Mertz Nørgård, Rikke Guldberg, Kim Oren Gradel

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Birthe Krogh RasmussenDepartment of Neurology, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.
Steinbjørn HansenDepartment of Oncology, Odense University Hospital, 5000, Odense C, Denmark. steinbjoern.hansen@rsyd.dk.ORCID http://orcid.org/0000-0001-5651-6493
René J LaursenDepartment of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark.
Michael KosteljanetzDepartment of Neurosurgery, Copenhagen University Hospital, Copenhagen, Denmark.
Henrik SchultzDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Bente Mertz NørgårdInstitute of Clinical Research, University of Southern Denmark, Odense C, Denmark.
Rikke GuldbergInstitute of Clinical Research, University of Southern Denmark, Odense C, Denmark.
Kim Oren GradelInstitute of Clinical Research, University of Southern Denmark, Odense C, Denmark.

Funding

The Danish Cancer Society R94-A5827
6 · The paper itself

Abstract

In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I-IV showed decreasing survival with increasing grade. Glioma grade I-IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.

Indexed as

AdolescentAdultAgedAge of OnsetBrain NeoplasmsDenmarkEpilepsyFemaleGliomaHeadacheHumansIncidenceMaleMiddle AgedPrognosisProspective StudiesEpidemiologyGliomaPrognosisSurvivalSymptoms

Identifiers

PMID28861666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.